Open AccessLncRNAs as the Regulators of Brain Function and Therapeutic Targets for Alzheimer’s Disease
Author(s) -
Yuqing Liu,
Xin Chen,
Yutong Che,
Hongli Liu,
Zheyu Zhang,
Weijun Peng,
Jingjing Yang
Publication year - 2022
Publication title -
aging and disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.808
H-Index - 54
ISSN - 2152-5250
DOI - 10.14336/ad.2021.1119
Subject(s) - disease , dementia , mechanism (biology) , pathogenesis , bioinformatics , medicine , long non coding rna , alzheimer's disease , function (biology) , biology , neuroscience , rna , genetics , gene , immunology , pathology , philosophy , epistemology
Alzheimer's disease (AD) is the most common type of dementia and a serious threat to the health and safety of the elderly population. It has become an emerging public health problem and a major economic and social burden. However, there is currently no effective treatment for AD. Although the mechanism of AD pathogenesis has been investigated substantially, the full range of molecular factors that contribute to its development remain largely unclear. In recent years, accumulating evidence has revealed that long non-coding RNAs (lncRNAs), a type of non-coding RNA longer than 200 nucleotides, play important roles in multiple biological processes involved in AD pathogenesis. With the further exploration of genomics, the role of lncRNA in the pathogenesis of AD has been phenotypically or mechanistically studied. Herein, we systematically review the current knowledge about lncRNAs implicated in AD and elaborate on their main regulatory pathways, which may contribute to the discovery of novel therapeutic targets and drugs for AD.